Provision of EPR services
- Comprador
- NORTH CHESHIRE & MERSEY NHS FOUNDATION TRUST
- Publicado
- 2026-11-16
- Plazo
- No indicado
- Fuentes
- UK_FTS
- Valor
- No indicado
Descripción
La descripción está en el idioma de la fuente.
This transparency notice concerns the proposed direct award of a new agreement by North Cheshire & Mersey NHS Foundation Trust (the Trust) to DH OpCo UK Ltd for the continued provision, support and maintenance of the Trust's existing Electronic Patient Record (EPR) services, including the Lorenzo and Ormis applications and associated existing interfaces, together with Lorenzo PatientAide and its associated implementation, configuration, support and maintenance services. Lorenzo PatientAide is an additional module and was not included within the Trust's original agreement. The proposed agreement is intended to preserve the safe and continuous operation of clinically critical EPR services while the Trust undertakes a compliant re-procurement and, if required, implements and transitions to a replacement solution. The Trust may undertake that future procurement independently or in collaboration with another NHS organisation, depending on approved requirements and arrangements at that time. The Trust's existing arrangements contain options to extend the incumbent services beyond 23 November 2026 through up to two further 12-month periods, potentially providing continuity until November 2028. While these provisions provide short-term flexibility, no further contractual extension rights exist beyond November 2028. The proposed term reflects the Trust's current programme for procuring and implementing its future EPR arrangements, including the time required to complete the procurement, implementation, migration, integration, testing, training, clinical-safety assurance and transition activities. The Trust has considered the extension rights available under the existing arrangements, including the potential for continuity until November 2028. However, those rights do not provide a reasonable alternative to the proposed contract. They expire before the Trust's revised EPR programme allows sufficient time to complete the planned EPR mini-competition and associated approval processes, and then safely implement the replacement solution, including configuration, data migration, integration, testing, training, clinical-safety assurance and deployment. The additional period to 30 November 2029 is therefore required to maintain continuity while those activities are completed. Without it, the existing arrangements could end before the replacement EPR is operational, creating unacceptable clinical, operational and business-continuity risks. The proposed term is a time-limited continuity measure to support transition to a replacement EPR and is not a longer-term commitment to the incumbent solution. The Trust does not consider competition to be permanently absent: the proposed direct award does not extend to the future replacement EPR, which is intended to be procured separately through competition.
Suscripción
Consulte gratis el resumen de cada anuncio. Los enlaces al anuncio oficial y sus documentos, los permisos de construcción y el acceso MCP personal requieren una suscripción de pago activa.
Leer